Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs J M Smucker Co (SJM) Price & Performance

Novartis AGTrade
J M Smucker CoTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs J M Smucker Co — how do they compare? Novartis AG trades at $152.57 (market cap $295.37B), while J M Smucker Co trades at $118.9 (market cap $12.54B). The key difference: Novartis AG is far larger — about 23.6× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.82%). Which is the better fit depends on your goals.

NVSSJM
Market Cap
$295.37B$12.54B
Sector
HealthConsumer Staples
52-Week High
$168.62$126.35
52-Week Low
$119.31$89.53
Enterprise Value
$336.69B$19.57B
Dividend Yield
3.07%3.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.

The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.

J M Smucker Co

SJM trades at $118.79, up 0.61% today, with a bullish technical signal and analyst consensus price target of $125.11. Recent earnings have shown beats in Q4 2025 and Q1 2026, but the company reported a net loss of $1.23B in 2025, with negative profit margins and ROE. Cash flow from operations remains strong at $1.21B, supporting a dividend increase to $1.12 per share, marking 25 consecutive years of growth. The stock is supported by positive media coverage highlighting value and growth potential.

The outlook is mixed; strong cash flow and dividend growth provide stability, but profitability challenges and high debt levels pose risks. Analyst sentiment is predominantly buy-rated, suggesting upside potential, though investors must weigh fundamental weaknesses against technical and sentiment positives for balanced decision-making.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About J M Smucker Co

J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.

Read more on SJM